RESUMEN
Aim: Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury. However, ATMP adoption requires adjustments to current clinical practices and frameworks. This study investigates the readiness of the Irish healthcare system to adopt licensed ATMPs. Materials & methods: Scoping review, guided by the preferred reporting items for systematic reviews and meta-analyses - scoping review extension. A systematic search of English articles from 2013 to 2023 (published and grey literature) will be conducted.Results: Findings will be presented via narrative summary, graphical and tabular formats.Discussion: Review findings will be discussed in the context of recommendations that will inform national policy and strategy on the adoption of ATMPs in Ireland.
This study examines whether Ireland's healthcare system is ready to use new kinds of medicines called advanced therapy medicinal products (ATMPs). These medicines are made from genes, tissues or cells and can be effective in treating certain diseases. However, delivering these medicines might mean changing current practices in clinics and hospitals.A scoping review will examine publications from 2013 to 2023 that focus on this topic. Results will be reported via narrative summary, graphs and tables. A discussion of the findings will be completed to inform recommendations for preparing the Irish healthcare system to deliver ATMPs.Ethics and dissemination: Ethical approval is not required for this scoping review. Findings will be disseminated through publication, stakeholder meetings and public engagement.